- Home
- ZVSA vs NVVE Comparison
ZVSA vs NVVE Comparison
Compare ZVSA & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- NVVE
- Stock Information
- Founded
- ZVSA 2014
- NVVE 1996
- Country
- ZVSA United States
- NVVE United States
- Employees
- ZVSA N/A
- NVVE N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- NVVE Oil Refining/Marketing
- Sector
- ZVSA Health Care
- NVVE Energy
- Exchange
- ZVSA Nasdaq
- NVVE Nasdaq
- Market Cap
- ZVSA 2.5M
- NVVE 2.8M
- IPO Year
- ZVSA N/A
- NVVE N/A
- Fundamental
- Price
- ZVSA $1.10
- NVVE $2.82
- Analyst Decision
- ZVSA Strong Buy
- NVVE
- Analyst Count
- ZVSA 1
- NVVE 0
- Target Price
- ZVSA $240.00
- NVVE N/A
- AVG Volume (30 Days)
- ZVSA 243.8K
- NVVE 11.5K
- Earning Date
- ZVSA 11-14-2024
- NVVE 11-12-2024
- Dividend Yield
- ZVSA N/A
- NVVE N/A
- EPS Growth
- ZVSA N/A
- NVVE N/A
- EPS
- ZVSA N/A
- NVVE N/A
- Revenue
- ZVSA N/A
- NVVE $5,144,831.00
- Revenue This Year
- ZVSA N/A
- NVVE $200.61
- Revenue Next Year
- ZVSA N/A
- NVVE $109.43
- P/E Ratio
- ZVSA N/A
- NVVE N/A
- Revenue Growth
- ZVSA N/A
- NVVE N/A
- 52 Week Low
- ZVSA $0.98
- NVVE $2.82
- 52 Week High
- ZVSA $25.00
- NVVE $72.70
- Technical
- Relative Strength Index (RSI)
- ZVSA 41.83
- NVVE 30.04
- Support Level
- ZVSA $0.99
- NVVE $3.31
- Resistance Level
- ZVSA $1.20
- NVVE $3.69
- Average True Range (ATR)
- ZVSA 0.08
- NVVE 0.22
- MACD
- ZVSA 0.04
- NVVE -0.05
- Stochastic Oscillator
- ZVSA 54.55
- NVVE 0.00
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.